

CITATION REPORT

List of articles citing

Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease

DOI: 10.1111/apt.12749

Alimentary Pharmacology and Therapeutics, 2014, 39, 1349-6

Source: <https://exaly.com/paper-pdf/59050665/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
146	Combining genetic and nongenetic biomarkers to realize the promise of pharmacogenomics for inflammatory diseases. 2014 , 15, 1931-40		4
145	Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease. 2014 , 14, 599-609		1
144	Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis. 2014 , 89, 1621-35		61
143	Maintenance therapy for Crohn's disease: should it be indefinite?. 2015 , 27, 1115-25		2
142	Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 1055-65	6.1	49
141	Pharmacologic therapy for inflammatory bowel disease refractory to steroids. 2015 , 8, 257-69		17
140	Managing immune checkpoint-blocking antibody side effects. 2015 , 76-83		271
139	Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. 2015 , 27, 804-12		28
138	Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 419-28	6.1	69
137	Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease. 2015 , 11, 317-27		7
136	Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. 2015 , 148, 344-54.e5; quiz e14-5		191
135	Pharmacological therapy of spondyloarthritis. 2015 , 16, 1495-504		10
134	Indian Society of Gastroenterology consensus statements on Crohn's disease in India. 2015 , 34, 3-22		10
133	Biologic agents for IBD: practical insights. 2015 , 12, 537-45		196
132	Association of serum VEGF with clinical response to anti-TNF therapy for Crohn's disease. 2015 , 76, 288-293		5
131	Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment. 2017 , 22, 918-926		19
130	Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1999-2015	4.5	71

129	How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 998-1009	4.5	15
128	Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan. 2016 , 16, 82		3
127	World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. 2016 , 50, 803-818		77
126	[Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease]. 2016 , 39, 265-272		2
125	Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease. 2016 , 39, 265-272		
124	Patient-Physician Communication in the 21st Century. 2016 , 37, 347-349		1
123	Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 322-9	4.7	24
122	Efficacy and Safety Profile of Anti-tumor Necrosis Factor- β Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect Comparisons. 2016 , 38, 1342-1358.e6		21
121	Manejo práctico de la intensificación del tratamiento biológico en los pacientes con enfermedad inflamatoria intestinal. 2016 , 15, 96-103		
120	Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 771-2	6.1	1
119	Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 30-51	6.1	171
118	The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-naïve Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 170-80	6.1	33
117	Comparable outcomes of the consistent use versus switched use of anti-tumor necrosis factor agents in postoperative recurrent Crohn's disease following ileocolonic resection. <i>International Journal of Colorectal Disease</i> , 2016 , 31, 1751-1758	3	4
116	Demonstration of Functional Similarity of Proposed Biosimilar ABP'501 to Adalimumab. 2016 , 30, 339-51		39
115	Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 880-5	4.5	29
114	Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. 2016 , 16, 1277-90		30
113	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016 , 48, 360-70	3.3	29
112	A mechanistic review on plant-derived natural compounds as dietary supplements for prevention of inflammatory bowel disease. 2016 , 10, 745-58		30

111	Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment. 2016 , 10, 1186-93		26
110	Approach to Optimize Anti-TNF- α Therapy in Patients With IBD. 2016 , 14, 83-90		12
109	The management of immune-related adverse events associated with immune checkpoint blockade. 2016 , 1, 89-97		11
108	Anti-TNF α Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 791-797	4.5	7
107	Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease. 2017 , 52, 1086-1092		23
106	Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1382-1393	4.5	18
105	Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1291-1302	6.1	160
104	French national consensus clinical guidelines for the management of Crohn's disease. <i>Digestive and Liver Disease</i> , 2017 , 49, 368-377	3.3	13
103	Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease. 2017 , 46, 589-601		2
102	Management of patients with inflammatory bowel disease and spondyloarthritis. 2017 , 10, 1363-1374		11
101	Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1301-1315	4.5	19
100	Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 3-13	6.1	127
99	Novel, Anti-hTNF- α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development. <i>Frontiers in Immunology</i> , 2017 , 8, 1780	8.4	21
98	Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. 2017 , 103, 405-421		31
97	Regulatory role of NKG2D+ NK cells in intestinal lamina propria by secreting double-edged Th1 cytokines in ulcerative colitis. 2017 , 8, 98945-98952		5
96	Aronia berry (<i>Aronia mitschurinii</i> [Viking]) inhibits colitis in mice and inhibits T cell tumour necrosis factor- β secretion. 2018 , 44, 48-57		13
95	Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1185-1192	4.5	29
94	Therapy for Crohn's Disease: a Review of Recent Developments. 2018 , 20, 19		17

93	Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 763-772	6.1	48
92	Toxicity profiles of immunotherapy. 2018 , 181, 91-100		40
91	Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2018 , 113, 276-282	0.7	22
90	Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. 2018 , 10, 203-213		6
89	Overview of Diagnosis and Medical Treatment of Inflammatory Bowel Diseases. 2018 , 1-15		
88	Crude leaf extracts of Piperaceae species downmodulate inflammatory responses by human monocytes. <i>PLoS ONE</i> , 2018 , 13, e0198682	3.7	3
87	How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. 2018 , 12, 797-810		23
86	Anti-TNF Therapy in Crohn's Disease. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	110
85	The state of the art on treatment of Crohn's disease. 2018 , 53, 989-998		21
84	Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients. 2018 , 2018, 6317057		11
83	Treatment Perspectives in Crohn's Disease. 2018 , 98, 135-142		8
82	Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 394-409	6.1	79
81	Earlier discontinuation of TNF-inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 386-396	6.1	12
80	Kidney Complications of Immune Checkpoint Inhibitors: A Review. 2019 , 74, 529-537		34
79	Therapeutic Drug Monitoring Increases Drug Retention of Anti-Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1276-1282	4.5	3
78	Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process. 2019 , 11,		9
77	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. 2019 , 68, s1-s106		557
76	In the absence of head-to-head trials, what do real world studies tell us about the comparative effectiveness of biologics in Crohn's disease. 2019 , 38-39, 101619		1

75	Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor. <i>Frontiers in Pharmacology</i> , 2019 , 10, 671	5.6	36
74	Network meta-analysis to inform positioning of biologics in patients with Crohn's disease: Promise and perils. 2019 , 38-39, 101614		2
73	A specific gene-microbe interaction drives the development of Crohn's disease-like colitis in mice. 2019 , 4,		50
72	Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease. 2019 , 19, 547-555		2
71	Accuracy of the new rapid test for monitoring adalimumab levels. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819828238	4.7	9
70	Quality of life of patients with inflammatory bowel disease using immunobiological therapy. 2019 , 39, 107-114		1
69	Treatment sequence network meta-analysis in Crohn's disease: a methodological case study. 2019 , 35, 733-756		9
68	Engineered and wild-type <i>L. lactis</i> promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa. 2019 , 35, 45		9
67	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1357-1366	4.5	3
66	Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. <i>PLoS ONE</i> , 2019 , 14, e0225572	3.7	8
65	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. 2019 , 4, 31-58		6
64	Co-expression of membrane-bound TNF-alpha type 1 and 2 receptors differ in the subsets of immunocompetent cells. 2019 , 207, 1-5		3
63	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. 2019 , 71, 5-32		178
62	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. 2019 , 71, 2-29		137
61	Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan. 2020 , 23, 80-85		2
60	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. 2020 , 14, 4-22		320
59	Anti-tumour necrosis factor- α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. 2020 , 5, 276-284		19
58	Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOt Randomized Controlled Trial. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1627-1635	4.5	14

57	Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. 2020 , 14, 694-709		54
56	Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study. 2021 , 9, 329-338		1
55	Pathophysiology of Crohn's disease inflammation and recurrence. 2020 , 15, 23		19
54	Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand. 2020 , 23, 1302-1310		1
53	Immune modulatory effect of a novel 4,5-dihydroxy-3,3',4'-trimethoxybibenzyl from <i>Dendrobium lindleyi</i> . <i>PLoS ONE</i> , 2020 , 15, e0238509	3-7	4
52	Certolizumab pegol for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 2020 ,	5-2	
51	Impact of remission on worries experienced by patients receiving biologic therapy for inflammatory bowel disease. 2020 , 18, 28-33		
50	Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review. 2020 , 20, 211		6
49	Associations Between Obesity and the Effectiveness of Anti-Tumor Necrosis Factor- α Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis. 2020 , 54, 729-741		10
48	Association between preoperative tumor necrosis factor alpha inhibitor and surgical site infection after surgery for inflammatory bowel disease: a systematic review and meta-analysis. 2021 , 51, 32-43		1
47	Histoplasmosis in Inflammatory Bowel Disease with Tumor Necrosis Factor-Alpha Inhibitors: Safe to Continue Biologics?. 2021 , 66, 190-198		3
46	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 106-122	4-5	6
45	Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn's Disease. <i>Gut and Liver</i> , 2021 , 15, 92-99	4-8	0
44	Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 84-85	6-1	0
43	Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: medical treatment.. <i>Frontline Gastroenterology</i> , 2022 , 13, 168-170	2-6	0
42	Guía de práctica clínica 2021 para el diagnóstico, el tratamiento y el seguimiento de pacientes con espondiloartritis periférica. Asociación Colombiana de Reumatología. <i>Revista Colombiana De Reumatología</i> , 2021 , 29, 44-44	0-2	
41	Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6-3	2
40	Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort. <i>PLoS ONE</i> , 2016 , 11, e0158017	3-7	75

39	A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. <i>ClinicoEconomics and Outcomes Research</i> , 2014 , 6, 431-43	1.7	11
38	Real-life outcome of anti-tumor necrosis factor in the ambulatory treatment of ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 3282-90	5.6	15
37	Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2018 , 24, 3567-3582	5.6	27
36	Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn's disease. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2017 , 8, 193-200	3	10
35	What Is the Best Possible Therapy for My Crohn's Disease? State-of-the-Art Therapy for Newly Diagnosed Crohn's Disease. 2015 , 59-71		
34	Anti-TNF Biologic Therapies Other than Infliximab. 2017 , 401-416		
33	Regulatory Perspectives on Biopharmaceuticals for Chronic Inflammatory Diseases in North Africa: A Narrative Review. <i>Open Rheumatology Journal</i> , 2019 , 13, 72-84	0.2	
32	Guía de práctica clínica 2021 para el diagnóstico, el tratamiento y el seguimiento de pacientes con espondiloartritis periférica. Asociación Colombiana de Reumatología. <i>Reumatología Clínica</i> , 2021 ,	0.9	
31	Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology.. <i>Przegląd Gastroenterologiczny</i> , 2021 , 16, 257-296	6	2
30	Medical Therapy for Crohn's Disease. 2022 , 781-798		
29	Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
28	Integration of Surgery with Medical Therapy in Treating Anal Fistulas. <i>Coloproctology</i> , 2021 , 1-18		
27	Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1.. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 790386	5.7	1
26	2021 clinical practice guidelines for the diagnosis, treatment, and follow-up of patients with peripheral spondyloarthritis. Colombian Association of Rheumatology.. <i>Reumatología Clínica (English Edition)</i> , 2022 ,	0.1	
25	Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases.. <i>Therapeutic Advances in Gastroenterology</i> , 2022 , 15, 17562848211068659	4.7	0
24	Does Disease Activity After Induction Treatment With Biologics Predict Short-Term Outcome in Crohn's Disease and Ulcerative Colitis?. <i>Inflammatory Bowel Diseases</i> , 2022 ,	4.5	
23	2021 clinical practice guidelines for the diagnosis, treatment, and follow-up of patients with peripheral spondyloarthritis. Colombian Association of Rheumatology. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2022 , 29, 44-56	0.1	
22	Model-Based Meta-Analysis on the Efficacy of Biologics and Small Targeted Molecules for Crohn's Disease.. <i>Frontiers in Immunology</i> , 2022 , 13, 828219	8.4	0

21	Aktualisierte S3-Leitlinie Diagnostik und Therapie des Morbus Crohn [Der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) [August 2021] AWMF-Registernummer: 021-004. <i>Zeitschrift Für Gastroenterologie</i> , 2022 , 60, 332-418	1.6	5
20	Long-term clinical and real-world experience with Crohn's disease treated with anti-tumor necrosis factor- α antibodies.. <i>Intestinal Research</i> , 2022 ,	4.1	
19	Association between preoperative biologic use and surgical morbidity in patients with Crohn's disease.. <i>International Journal of Colorectal Disease</i> , 2022 , 1	3	0
18	Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.. <i>American Journal of Gastroenterology</i> , 2022 ,	0.7	1
17	Integration of Surgery with Medical Therapy in Treating Anal Fistulas. <i>Coloproctology</i> , 2022 , 519-536		
16	Personalized medicine in inflammatory bowel disease: perspectives on Asia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> ,	4	0
15	Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases. <i>Frontiers in Pharmacology</i> , 13,	5.6	0
14	Certolizumab pegol for maintenance of medically induced remission in Crohn's disease. <i>The Cochrane Library</i> , 2022 , 2022,	5.2	0
13	Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease. <i>Digestive and Liver Disease</i> , 2022 ,	3.3	
12	Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine. <i>Biomedicines</i> , 2022 , 10, 1735	4.8	0
11	Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease.		0
10	Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease. 2022 , 34, 983-992		0
9	Impact of a physician-led exercise programme on quality of life, muscle mass and clinical response in inflammatory bowel disease patients during induction with disease-modifying therapy: a study protocol. 2022 , 9, e000959		0
8	Anti-TNF Therapies Suppress Adipose Tissue Inflammation in Crohn's Disease. 2022 , 23, 11170		0
7	Integrating Radiomics With Clinoradiological Scoring Can Predict High-Risk Patients Who Need Surgery in Crohn's Disease: A Pilot Study.		0
6	Introducing Biosimilars into Current Inflammatory Bowel Disease Treatment Algorithms. 34-41		0
5	Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease. 2022 , 22,		1
4	Caracterización clínica y terapéutica de una cohorte multicéntrica de pacientes con enfermedad inflamatoria intestinal en Colombia. 2022 ,		0

- 3 Oral Infliximab Nanomedicines for Targeted Treatment of Inflammatory Bowel Diseases. **2023**, 106379 ○
- 2 Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology. **2023**, 55, 442-453 ○
- 1 Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study. **2023**, 12, 2503 ○